Pricing Log in Create free account
Friday 6 November 2026 Export SMMT’s income statement to Excel — free account

Summit Therapeutics PLC

SMMT Healthcare Biotechnology

Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.

EPS
+63.2%
Free cash flow
−112.8%

Quarter to June 2026, against a year earlier

15.85 1.66 +11.70%
Market cap
$11.3B
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
3/9
Altman Z
0.88
Beneish M
−5.00
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Summit Therapeutics PLC (SMMT) Total debt

Alert me on Total debt

Summit Therapeutics PLC's total debt at the end of fiscal 2023 was $100.0M, down 79.8% from $494.5M in fiscal 2022. At the end of the quarter to 31 March 2024 it was $100.0M. Summit Therapeutics PLC ranks 89th of 569 Biotechnology companies by total debt.

Total debt, annual

Embed this chart

Annual newest first

Period Total debt Change
FY2023 $100.0M (79.78%)
FY2022 $494.5M 659,286.67%
FY2020 $75.0K (82.31%)
FY2019 $423.9K —

Quarterly newest first

Period Total debt Change
Mar 2024 $100.0M 0.00%
Dec 2023 $100.0M 0.00%
Jun 2023 $100.0M 0.00%
Mar 2023 $100.0M (79.78%)
9 more quarters

Total debt against peers

Company Total debt
JAZZ Jazz Pharmaceuticals PLC compare $5.6B
BMRN BioMarin Pharmaceutical Inc. compare $4.2B
HALO Halozyme Therapeutics, Inc. compare $3.3B
BBIO BridgeBio Pharma, Inc. compare $1.9B
ASND Ascendis Pharma A/S compare $523.3M
TECH Bio-Techne Corp compare $200.0M
SMMT Summit Therapeutics PLC $100.0M
PCVX Vaxcyte, Inc. compare $14.0M
KYMR Kymera Therapeutics, Inc. compare $602.0K

What Total debt is

Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.

Long Term Debt (Total) + Current Part of Debt

The full definition of Total debt →

More on SMMT